• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

davis.j@unimelb.edu.au

Credentials


Position
Honorary (Fellow)
Department of Medicine
Education
PhD
University of Melbourne
Bachelors Degree (Honours)
University of Melbourne
ORCID

0009-0001-4887-5960

Dr Joanne Davis

Honorary (Fellow)
Department of Medicine

50 Scholarly works
0 Projects

HIGHLIGHTS

  • 2025

    Journal article

    Immunological responses to blinatumomab treatment in B-acute lymphoblastic leukaemia (B-ALL) patients - australasian leukemia and lymphoma group ALL08 blam study
    DOI: 10.1182/blood-2025-3341
  • 2025

    Journal article

    Post-Transplant Anti-Thymocyte Globulin (ATG) Exposure in Recipients of Reduced-Intensity Conditioning Transplantation Receiving ATG As Gvhd Prophylaxis Is Predictive of Gvhd, Relapse-Free Survival.
    DOI: 10.1016/j.jtct.2025.01.447
  • 2024

    Journal article

    Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment
    DOI: 10.1182/blood-2024-199866
  • 2024

    Journal article

    A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome
    DOI: 10.1038/s41409-023-02195-x
  • 2024

    Journal article

    Modified cell trace violet proliferation assay preserves lymphocyte viability and allows spectral flow cytometry analysis
    DOI: 10.1002/cyto.a.24830
  • 2023

    Journal article

    A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma
    DOI: 10.1186/s13148-023-01427-7
  • 2021

    Journal article

    Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
    DOI: 10.1186/s12967-021-03136-2
Joanne Davis

RECENT SCHOLARLY WORKS

  • 2021

    Journal article

    Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients
    DOI: 10.3389/fimmu.2021.749094
  • 2020

    Journal article

    Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy
    DOI: 10.1182/BLOODADVANCES.2020002810
  • 2020

    Conference Proceedings

    Venetoclax or Ruxolitinib Depletion of Recipient NK Cells, in Combination with Reduced Intensity Conditioning, Improves Donor Cell Engraftment without Gvhd in a Mouse Model of Allosct.
    DOI: 10.1016/j.bbmt.2019.12.033

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224